US (or EU) ANDA: Fail f2 but pass BE? [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-09-02 02:29 (1043 d 23:57 ago) – Posting: # 23260
Views: 5,446

Thanks Osama.

That's my thinking as well since the BE studies were ~ 100% in ratios and reasonably sized.
But explaining to those non-pk/bioparm management f**ls who keep asking for risk assessment BS is a challenge.

❝ What about if you start with sampling time points @ 10 min ( EMA) and not @ 5min ( FDA)?

❝ have you tried with bootstrapping to overcome the high variability in the early sampling time points?


Unfortunately the guidance asked for 5 and 10 mins and on... evaluating the data now to see if there is need to evaluate..

john

Complete thread:

UA Flag
Activity
 Admin contact
23,434 posts in 4,931 threads, 1,674 registered users;
48 visitors (0 registered, 48 guests [including 18 identified bots]).
Forum time: 02:27 CEST (Europe/Vienna)

For every expert there is an equal and opposite expert.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5